NEW YORK--(BUSINESS WIRE)--The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) (“Sagent Pharmaceuticals” or “the Company”) in connection with the sale of the Company to Nichi-Iko Pharmaceutical Co., Ltd. Under the terms of the transaction, Sagent Pharmaceuticals shareholders will receive $21.75 in cash for each share of Sagent Pharmaceuticals stock they own.
Click here to learn about the case: http://docs.wongesq.com/SGNT-Info-Request-Form-1278. There is no cost or obligation to you.
The investigation concerns whether the Board of Sagent Pharmaceuticals breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Nichi-Iko Pharmaceutical Co., Ltd. is underpaying for Sagent Pharmaceuticals shares.
If you own common stock in Sagent Pharmaceuticals and wish to obtain additional information, please contact Vincent Wong, Esq. either via email email@example.com, by telephone at 212.425.1140, or visit http://docs.wongesq.com/SGNT-Info-Request-Form-1278.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.